TTR – Transthyretin
StressMarq Biosciences has developed an extensive range of fibrillar, oligomeric and monomeric protein preparations for use in neurodegenerative disease research including alpha synuclein, beta synuclein, gamma synuclein, tau, amyloid beta, SOD1 and TTR. Our goal is to be the world leader in the development and supply of active, pathology-inducing protein aggregates to assist scientists with disease model development and accelerate neurodegenerative disease drug discovery.
Transthyretin (TTR) misfolding is associated with amyloid diseases. Both the L55P and Y78F mutants are amyloidogenic.1,2 TTR aggregation can be measured via turbidity.3
StressMarq manufactures L55P and Y78F TTR filaments and monomer constructs for use in neurodegenerative disease research.
- Human Recombinant Transthyretin L55P Variant Filaments | catalog# SPR-464
- Human Recombinant Transthyretin L55P Variant Monomers | catalog# SPR-451
- Human Recombinant Transthyretin Y78F Variant Filaments | catalog# SPR-465
- Human Recombinant Transthyretin Y78F Variant Monomers | catalog# SPR-452
1. Lashuel, H.A. et al. (1999) Biochem. 38(41):13560-73.
2. Terazaki, H. et al. (2006) Lab. Investigation. 86, 23-31
3. Robinson, L. Z., Reixach, N. (2014) Biochem. 53(41):6496-510
Supplemental Learning Materials
Technical Support Resources
- Handling Instructions | TTR
- Protocols | Neuro Proteins
- Sonication Protocol | PFFs
- Frequently Asked Questions | Neuro Proteins
Selected Publications from the StressMarq Blog
Have a question about TTR?